CUE
CUE Energy Resources Limited
🇦🇺 ASX
⚡️ ENERGY
👑 Overview
📈 Performance
💰 Dividends
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
-4.32%
Annual Growth
5 years average annual growth
💰
31.25%
Annual dividend yield
Based on the most recent dividend
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
1
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Cue Energy Resources Ltd. engages in the exploration, development and production of oil and gas. The company is headquartered in Melbourne, Victoria. In Australia, it has interests in three production assets, Mereenie, Palm Valley, and Dingo Fields, situated in the Amadeus Basin within the onshore Northern Territory. The Mereenie field produces gas which is transported through the Northern Gas pipeline to serve the Eastern Australia gas market. The Palm Valley field is 100 kilometers west of Alice Springs and produces gas, which is transported through the Amadeus and Northern Gas pipeline and sold into the Northern Territory and Eastern Australia gas markets. The Dingo field produces gas, which is processed at the Brewer Estate processing facility located near Alice Springs. In New Zealand, it holds a 5% interest Petroleum Mining Permit (PMP) 38160, which contains the Maari and Manaia producing oilfields. In Indonesia, it holds interests in Mahato PSC and Sampang PSC.
📈 Performance
Price History
+30.67%
1M
1Y
10Y
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💰 Dividends
Payouts
💰 Annual Dividend Yield*
31.25%
💰 Annual Dividend Earnings Per $1,000 invested**
$312.50
💰 Most Recent Dividend Franked Percentage Estimate
0.00%
💰 Average Dividend Franked Percentage Estimate
0.00 %
💰 Dividend reinvestment
* Based on the most recent dividend
** Calculated by multiplying the most recent dividend yield by $1,000
Estimate your dividend
If you held
$
of CUE, your last dividend payment(s) would have been:
$ 909.09
on Thu Sep 26 2024
$ 1,739.13
on Fri Apr 05 2024
*Disclaimer: The information provided in this calculator is only a model to show you how long you need to invest for to achieve your goal, based on several factors, including past performance which is not an indicator of future performance. It is not a prediction and relies on assumptions, such as interest rates, that may vary and change the actual outcome. The results shown are only estimates and are not intended to be relied on when making a financial decision. Consider whether to get advice from a licensed financial adviser before making any financial decision.
Dividend History
1Y
5Y
10Y
Graph
Table
Year
Yearly Dividend Earnings Per Share
Franking Estimate
2024
$0.03
0.00%
2023
$0.00
0.00%
2022
$0.00
0.00%
2021
$0.00
0.00%
2020
$0.00
0.00%
2019
$0.00
0.00%
2018
$0.00
0.00%
2017
$0.00
0.00%
2016
$0.00
0.00%
2015
$0.00
0.00%
💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
💰 Price*
$0.10
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in CUE
1
📊 Total Capital Earnings
$-177.093
🔃 Average investment frequency
15 weeks
💵 Average investment amount
$629
⏰ Last time a customer invested in CUE
15 days
CUE investor breakdown
💵 Income of investors
More than 200k
50%
150k - 200k
100k - 150k
50k - 100k
Less than 50k
50%
👶 Age of investors
18 - 25
26 - 34
35 - 90
100%
🙋 Legal gender of investors
Female
Male
100%
Pearlers who invest in CUE also invest in...
RMD
ResMed, Inc. engages in providing digital health and cloud-connected medical devices. The company is headquartered in San Diego, California and currently employs 9,980 full-time employees. The Company, through its subsidiaries, in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases. The company also operates a Software as a Service (SaaS) business in the United States and Germany that includes out-of-hospital software platforms designed to support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. The Company’s segments include Sleep and Respiratory Care and SaaS. Its products and solutions are designed to improve patients' quality of life and reduce the impact of chronic disease. Its cloud-based digital health software applications, along with its devices, are designed to provide connected care to improve patient outcomes.
🙌 Performance (5Yr p.a)
13.54%
📊 Share price
$37.65 AUD
📈 HIGH PRICE GROWTH
🌳 ENVIRONMENTAL
🕊️ SOCIALLY AWARE
🩺 HEALTH CARE
Pilbara Minerals Ltd. engages in the exploration and evaluation of mineral properties. The company is headquartered in Perth, Western Australia and currently employs 917 full-time employees. The company went IPO on 2007-09-19. The firm is primarily engaged in the exploration, development, and mining of minerals in Australia. Its 100% owned Pilgangoora hard-rock lithium operation is located approximately 120 kilometers (kms) from Port Hedland in Western Australia’s resource-rich Pilbara region. The operation consists of two processing plants: the Pilgan Plant, located on the northern side of the Pilgangoora area and produces spodumene and tantalite concentrates, and the Ngungaju Plant is located to the south produces spodumene concentrate. The company owns 70% of the Mt Francisco project, which is located 50 km south-west of the Pilgangoora Project and hosts the large occurrence of outcropping pegmatites located nearby to Port Hedland. The company is also pursuing a proposed downstream joint venture (JV) for the development of an approximately 43,000 tons per annum (tpa) lithium carbonate equivalent (LCE) lithium chemical conversion facility in South Korea.
🙌 Performance (5Yr p.a)
159.70%
📊 Share price
$2.26 AUD
⛏️ MINING
IVV
IVV.AX was created on 2007-10-10 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.
🙌 Performance (5Yr p.a)
20.94%
📊 Share price
$63.52 AUD
📈 HIGH PRICE GROWTH
🇺🇸 UNITED STATES
RBTZ.AX was created on 2018-09-12 by BetaShares. The fund's investment portfolio concentrates primarily on theme equity. RBTZ.AX aims to track the performance of an index (before fees and expenses) that includes global companies involved in the production or use of robotics and artificial intelligence (A.l.) products and services.
🙌 Performance (5Yr p.a)
8.33%
📊 Share price
$15.00 AUD
🇦🇺 EX AUSTRALIA
🤖 TECHNOLOGY
📈 HIGH PRICE GROWTH
A200.AX was created on 2018-05-07 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The ETF currently has 6041.2m in AUM and 200 holdings. A200.AX aims to track the performance of an index (before fees and expenses) comprising 200 of the largest companies by market capitalisation listed on the ASX.
🙌 Performance (5Yr p.a)
4.17%
📊 Share price
$139.14 AUD
⛳️ DIVERSIFIED
💸 FINANCIALS
🇦🇺 AUSTRALIA
Want more shares? Try these...
CUF
CuFe Ltd. operates as an exploration company. The company is headquartered in Leederville, Western Australia. The company went IPO on 2005-10-13. Its main focus is its mature iron ore assets in Western Australia (JWD Iron Ore Project) and the Northern Territory (Yarram Iron Ore Project) and copper asset (Tennant Creek Copper Project). The JWD Iron Ore Project is located in Western Australia, 700 kilometers from Geraldton Port. The company holds a 50% interest in Gold Valley Iron and Manganese Pty Ltd, the owner of the iron ore rights over the Yarram project. The company owns 55% interest in the Tennant Creek project. The company owns West Arunta (niobium) and Tambourah (lithium) exploration tenure. The company owns North Dam Lithium and Rare Earths Project- E 15/1495, M15/1893 (certain mineral rights), and M15/1495. Its other projects include Bryah Basin Joint Venture Projects, Morck Well Project, Peak Hill Project and Mt Ida Iron Ore Project.
🙌 Performance (5Yr p.a)
-8.57%
📊 Share price
$0.01 AUD
⛏️ MINING
Cettire Ltd. is an online luxury goods retailer, which engages in luxury personal items such as clothing, shoes, bags, and accessories via their website. The company is headquartered in Melbourne, Victoria. The company went IPO on 2020-12-18. The firm is engaged in offering a selection of in demand personal luxury goods via its Website, cettire.com. The company has access to an extensive catalogue of more than 2,500 luxury brands and 500,000 products of clothing, shoes, bags, and accessories. The company sells a range of products from over 500 designers, which include a range of women's and men's wear from brands, such as Prada, Gucci, Saint Laurent, Balenciaga, and Valentino, among others. The firm's product categories include clothing, shoes, bags, and accessories. Its clothing category offers activewear, coats, jackets, jeans, knitwear, pants, and various others. Its shoes category offers boots, espadrilles, lace-up shoes, loafers, and various others. The Company’s bags category offers bag accessories, belt bags, clutch bags, crossbody bags and various others. The firm also offers accessories, such as belts, glasses, gloves, hats, and various others.
📊 Share price
$1.12 AUD
🛍️ CONSUMER
Clarity Pharmaceuticals Ltd. is a clinical stage radiopharmaceutical company. The company is headquartered in Eveleigh, New South Wales. The company went IPO on 2021-08-25. The firm is focused on developing theranostic (therapy and imaging) products, based on its platform SAR Technology. The company is progressing seven clinical trials with its three key products, SARTATE, SAR-bisPSMA, and SAR-Bombesin. SARTATE is developed for diagnosing, staging, and treating cancers that express somatostatin receptor 2 (SSTR2), including neuroblastoma and neuroendocrine tumors (NETs). SAR-bisPSMA is developed for diagnosing, staging, and treating cancers that express Prostate Specific Membrane Antigen (PSMA). SAR-Bombesin is developed for identifying and selecting patients for subsequent treatment of cancers that express a specific receptor called the gastrin releasing peptide receptor (GRPr), including breast cancer and prostate cancer. The company has a diverse range of products in clinical trials, which address both large indications as well as rare and orphan indications of cancer.
📊 Share price
$4.54 AUD
📦 LOGISTICS